Schering Plough Reports Preladenant Meets Primary Endpoint In Phase II Dose-Finding Trial For Parkinson’s Disease
Nov 25th 2008Drug InformationClinical Trials
Schering-Plough Corporation (NYSE: SGP) reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson’s disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented at the company’s 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
